Asporto Launched at the International Heart and Lung Transplantation Conference

The new Asporto // Heart Preservation Device by Hibernicor was launched on April 11th,2018 at the International Heart and Lung Transplant Conference in Nice (Fr).  The conference had 2665 attendees from over 45 countries who specialize in the multidisciplinary management and treatment of end-stage heart and lung disease.

Hibernicor completed the initial production of a light-weight carbon fiber device with an pioneering American carbon-fiber manufacturer. The Hibernicor carbon fiber insulated cooler and perfusion system is designed to double the preservation time of the donor heart.  The system is now ready for pre-clinical testing prior to FDA 510k approval.

Asporto controls the administration and circulation of a saline-based fluid to the donor heart during hypothermic storage in a carbon-fiber insulated shell cooled using thermoelectric technology. The heart is stored in a single-use sterile container.  Dr. Andrew Rivard – the company founder presented the Asporto device as one of 30 companies exhibiting at the ISHLT conference this year.

Dr. Rivard obtained his BA, MS, MD degrees from the University of Minnesota with a concentration on cardiovascular physiology. In 2002 he founded Hibernicor based upon research done in Minnesota at the Experimental Surgical Services.  He also developed an electronic medical record system (Praestro), was an innovator in many health care technologies focusing on heart valves, heart transplantation, and imaging. He is a diagnostic cardio-radiologist trained at the University of Florida and now works for the Cleveland Clinic in Abu Dhabi focusing on advanced cardiac imaging.


Hibernicor Selected as Finalist for Boston Pediatric Device Strategic Partner Challenge

Hibernicor has been selected as a finalist for the Boston Pediatric Device Consortium Strategic Partner Challenge after a comprehensive review of applications conducted by the Boston Pediatric Device Consortium (BPDC), the Innovation & Digital Health Accelerator at Boston Children’s Hospital (IDHA), and partner organizations.

  • Date/Time: Wednesday, December 6th, 8:00 am – 6:00 pm
  • Location: 300 Longwood Avenue, Boston, MA, 02115

Challenge winners will receive a combination of up to $50,000 in funding and/or mentorship opportunities. Strategic partners – including Boston Scientific, CryoLife, Edwards Lifesciences, Health Advances, Johnson & Johnson Innovation, Smithwise, and Ximedica – will provide strategic support for challenge winners focused on accelerating winning innovations towards commercialization.

The Boston Pediatric Device Consortium (BPDC) provides expertise and resources to device developers and manufacturers at each of the steps necessary for novel pediatric device development, in order to accelerate the pace of innovation. The BPDC is a collaborative of experts in engineering, clinical sciences, clinical trials design and performance, device development specialists, and industry partners whose primary goal is to develop and evaluate novel therapies for children. Leading the BPDC is Pedro del Nido, MD, the Chief of the Department of Cardiac Surgery at Boston Children’s Hospital, the William E. Ladd Professor of Child Surgery at Harvard Medical School, and medical device entrepreneur.


Hibernicor Announces Upgrade to the Asporto Software

The Asporto // Heart Preservation Device is a portable thermoelectric cooler for transporting the donor heart to heart transplant recipients.  The device consists of a microcontroller with touch-screen display, insulated container, peristaltic pump, AC to DC converter and a sterile disposable kit. The Asporto microcontroller has been upgraded to software version 5.02.  The completely new software allows the microcontroller to have better usage of memory-mapped pages for fault-tolerant and reliable continuation following power interruptions.  The new software takes advantage of a multi-tasking operating system which optimizes touchscreen, display and pump operations.

Hibernicor, Ltd is now incorporated in the United Kingdom, making the first official step to distributing Asporto in Europe.

Semi-finalist – 2009 Minnesota Cup business plan competition

With over 1000 entries to the 2009 Minnesota Cup, Hibernicor ranked in the Top 10  in the Biosciences category following a first round of judging.  The Minnesota Cup is an annual, statewide competition, which seeks out aspiring entrepreneurs and their breakthrough ideas.  The competition was hosted by the University of Minnesota and Wells Fargo for its fifth year.


Hibernicor begins discussions with the FDA on the pre-clinical research protocol

Hibernicor met with representatives of FDA’s Center for Devices and Radiologic Health (CDRH) on October 30th, 2008.  Based upon the discussions with the FDA, Hibernicor has finalized the pre-clnical research protocol necessary for 510k approval.

Research study shows that Asporto limits degradation of the donor heart

A recent study from the University of Minnesota using the Asporto heart preservation device was published in a nationally recognized peer reviewed journal. The study demonstrated that intermittent antegrade cardioplegia maintains a significantly higher pH in donor hearts. The study involved a series of animal hearts preserved using the conventional method of donor heart transportation (an insulated container) vs. hearts preserved in the Asporto heart preservation device. Use of the device limited the rapid formation of acidosis that causes irreversible heart muscle damage that occurs during the conventional method. (Progress in Transplantation, 2008; 18(2):127-133)

FDA and Hibernicor have a pre-IDE (Investigation Device Exemption) meeting.

Praesto software installed at the University of Minnesota

The electronic research record Praesto was implemented this month at the University of Minnesota’s Experimental Surgical Services. Richard W. Bianco, the GLP laboratory’s director was extremely satisfied with the conversion to the electronic format that will be used initially in the preclinical testing of new heart valves.

Asporto featured at the 27th Annual Meeting of the International Society for Heart and Lung Transplantation

Research completed at the University of Minnesota was presented at the 27th Annual Meeting of the International Society for Heart Lung Transplant. The study demonstrated the effectiveness of intermittent antegrade cardioplegia in reducing damage during prolonged storage of isolated heart.